An endothelin antagonist for resistant hypertension

Research output: Contribution to journalLetter

Abstract

I wish to provide a brief comment on the impressive randomised trial by Michael Weber and colleagues,1 which shows that the endothelin-receptor antagonist darusentan provides additional reductions in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs.
Original languageEnglish
Pages (from-to)636-636
Number of pages1
JournalThe Lancet
Volume375
Issue number9715
DOIs
Publication statusPublished - 22 Feb 2010
Externally publishedYes

Fingerprint

Antihypertensive Agents
Blood Pressure
Hypertension
Therapeutics
LU 135252
Endothelin Receptor Antagonists

Cite this

Naunton, Mark. / An endothelin antagonist for resistant hypertension. In: The Lancet. 2010 ; Vol. 375, No. 9715. pp. 636-636.
@article{3a512e9951cd403097cd8035c99f8cf7,
title = "An endothelin antagonist for resistant hypertension",
abstract = "I wish to provide a brief comment on the impressive randomised trial by Michael Weber and colleagues,1 which shows that the endothelin-receptor antagonist darusentan provides additional reductions in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs.",
author = "Mark Naunton",
year = "2010",
month = "2",
day = "22",
doi = "10.1016/S0140-6736(10)60262-0",
language = "English",
volume = "375",
pages = "636--636",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9715",

}

An endothelin antagonist for resistant hypertension. / Naunton, Mark.

In: The Lancet, Vol. 375, No. 9715, 22.02.2010, p. 636-636.

Research output: Contribution to journalLetter

TY - JOUR

T1 - An endothelin antagonist for resistant hypertension

AU - Naunton, Mark

PY - 2010/2/22

Y1 - 2010/2/22

N2 - I wish to provide a brief comment on the impressive randomised trial by Michael Weber and colleagues,1 which shows that the endothelin-receptor antagonist darusentan provides additional reductions in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs.

AB - I wish to provide a brief comment on the impressive randomised trial by Michael Weber and colleagues,1 which shows that the endothelin-receptor antagonist darusentan provides additional reductions in blood pressure in patients who have not attained their treatment goals with three or more antihypertensive drugs.

UR - http://www.scopus.com/inward/record.url?scp=76749156102&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)60262-0

DO - 10.1016/S0140-6736(10)60262-0

M3 - Letter

VL - 375

SP - 636

EP - 636

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9715

ER -